HomeIngredients › BHA & BHT (E320/E321)

Are BHA and BHT safe?

By LabelCop · Last updated 18 July 2026 · Sources: EFSA, FDA, FSSAI, WHO/JECFA, IARC, NTP

The short answer: two chemical cousins, treated differently by every regulator — and that split is the story.

What are BHA and BHT?

Which foods contain them?

What the regulators actually say

RegulatorStatusReasoning
EFSA / European UnionBoth permittedEFSA re-evaluated BHA in 2011 and BHT in 2012, concluding neither raises a genotoxicity (DNA-damage) concern and setting acceptable daily intakes — for BHT, 0.25 mg per kg of body weight per day. Both remain authorised antioxidants at limited levels.
FDA (United States)Permitted, both under reviewBoth are Generally Recognized as Safe (GRAS) — BHA since 1958, BHT as an antioxidant capped at 0.02% of a food's fat or oil content. In 2026 the FDA opened post-market reassessments of both: a request for information on BHA (February 2026) and on BHT, with scientific data due 13 July 2026.
FSSAI (India)Both permitted in specified foodsPermitted as antioxidants (INS 320, INS 321) under Schedule I of the food-additive regulations, typically as a combined synthetic-antioxidant maximum for each food category.
WHO / JECFAADIs setThe joint FAO/WHO expert committee set acceptable daily intakes of up to 0.5 mg/kg body weight for BHA and up to 0.3 mg/kg for BHT — levels it judges safe for lifetime daily consumption.
WHO / IARC (cancer agency)BHA "possibly carcinogenic"; BHT unclassifiedIARC rates BHA as Group 2B — possibly carcinogenic to humans — based on forestomach tumours in rodents. BHT is Group 3 — not classifiable, because the animal evidence was too limited. The US National Toxicology Program also lists BHA as "reasonably anticipated to be a human carcinogen".

Why do regulators disagree?

How LabelCop scores them

Frequently asked questions

Are BHA and BHT banned in India?

No. FSSAI permits both (INS 320 and INS 321) as antioxidants in specified foods within prescribed limits, usually as a combined maximum. Neither is banned in India, the US, the UK, the EU, Australia or Canada.

Is BHA a carcinogen?

The WHO's cancer agency (IARC) rates it Group 2B — "possibly carcinogenic to humans" — based on rodent forestomach tumours, and the US National Toxicology Program lists it as "reasonably anticipated to be a human carcinogen". Regulators still permit it because they judge the rodent mechanism may not apply to people and dietary exposure is low. LabelCop flags it on the strength of those classifications.

What's the difference between BHA and BHT?

They're chemical cousins doing the same job and are often used together. The key difference is the cancer verdict: BHA is IARC Group 2B (possibly carcinogenic); BHT is Group 3 (not classifiable — evidence too limited). That's why we treat BHA as higher risk.

Why is the FDA reviewing them in 2026?

Both were cleared as GRAS decades ago. In 2026 the FDA reopened post-market safety reassessments of both — a request for information on BHA in February, and on BHT with data due 13 July 2026. Being reviewed doesn't mean restricted; it means old decisions are being re-examined with newer data.

How do I avoid them?

Read the ingredients list for BHA, BHT, E320, E321, INS 320 or INS 321 — most common in fried snacks, instant noodles, cereals and edible oils. Or scan the label with LabelCop and they're flagged automatically, with the regulator reasoning shown.

Stop memorising E-numbers.

LabelCop reads any food label you photograph and flags antioxidants like BHA and BHT instantly — no barcode needed.

Join the early-access list

Sources

EFSA (2011): re-evaluation of BHA (E320) as a food additive · EFSA (2012): re-evaluation of BHT (E321) as a food additive · FDA (2026): assessment of BHA launched · FDA (2026): reassessment of BHT launched · US NTP Report on Carcinogens: BHA · WHO/IARC Monographs: classification list (BHA Group 2B, BHT Group 3) · FSSAI: Food Safety and Standards regulations — permitted antioxidants

Related ingredients: TBHQ (E319) · Sodium benzoate (E211) · Titanium dioxide (E171)

This article explains regulatory status and published scientific assessments in plain English. It is not medical advice.